Royalty Report: Medical, Diagnostic, Device – Collection: 1713

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6

Primary Industries

  • Medical
  • Diagnostic
  • Device
  • Delivery
  • Drugs
  • Pharmaceuticals
  • Diagnostic Substances

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1713

License Grant
The Licensors, two individuals, assigned all of their rights, title and interest throughout the world in, to and under certain improvements relating to blood analyzers and disposable syringes for use in medical analyzers in U.S. Patent No. 5,066,859, U.S. Patent Application Serial No. 07/789,088 and a Patent and Cooperation Treaty Patent Application entitled 'Hematocrit and Oxygen Saturation Blood Analyzer'.
License Property
U.S. Patent No. 5,066,859, 'Hematocrit and Oxygen Saturation Blood Analyzer'

IPSCIO Record ID: 378

License Grant
The Company has exclusive right to manufacture, market and distribute products utilizing automated retraction technology.
License Property
VanishPoint(R) products invented by 80% shareholder are designed specifically to prevent needlestick injuries and to prevent reuse.  The friction ring mechanism permits the automated retraction of the syringe needle into the barrel of the syringe, directly from the patient, after delivery of the medication is completed.

U.S. Patent 5,120,310, Issued June 9, 1992, entitled Nonreusable Syringe; U.S. Patent 5,188,613, Issued February 23, 1993, entitled Nonreusable Syringe with Safety Clip; U.S. Patent 5,267,961, Issued December 7, 1993, entitled Nonreusable Syringe with Safety Clip; Foreign Counterpart Patent Applications on the Nonreusable Syringe with Safety Clip corresponding to U.S. Patents 5,120,310 and 5,188,613 for Europe (Serial No. 92910361.2), China (Serial No. 92102245.X), India (Serial No. 186/CAL/92), Mexico (Serial No. 92-01493), and Taiwan (Serial No.  82205282); U.S. Patent 5,423,758, Issued June 13, 1995, Entitled Retractable Fluid Collection Device and a Counterpart Patent Cooperation Treaty Application Serial No. 94/13953, Entitled Blood Sampler, Filed December 6, 1994 designating all PCT countries; U.S. Patent 5,385,551, Issued January 31, 1995, Entitled Nonreusable Syringe with Front Retraction and a Counterpart Patent Cooperation Treaty Application Serial No.  PCT/US94/10235, Filed September 7, 1994 designating all PCT countries; U.S. Patent 5,389,076, Issued February 14, 1995, Entitled Single Use Medical Device with Retraction Mechanism and a Counterpart Patent Cooperation Treaty Application Serial No.  PCT/US95/03953, Filed March 31, 1995 designating all PCT countries; U.S. Patent Application Serial No. 380107, Filed January 30, 1995, Entitled Syringe Plunger Seal and Locking Assembly, and the right to file Patent Applications thereon in nearly any foreign country until January 30, 1996; and A new U.S. Patent Application filed in May, 1995, Entitled Tamperproof Retractable Syringe with Serial No. 08/438,954, and the right to file Patent Applications thereon in nearly any foreign country until May, 1996.

Field of Use
The field of use shall mean the syringe technology relating to the healthcare industry.

IPSCIO Record ID: 1233

License Grant
The agreement transfers, assigns and conveys all of its right, title and interest in and to  the Hematocrit Technology and any derivative thereof, including without limitation, ownership,  licensing, marketing, sales, distribution and manufacturing rights.

Licensor grants to an exclusive right and license in and to all of its right, title and interest in and to the Hematocrit Technology and any derivative thereof, to make, have made, use, sell, offer to sell, and import Products and to practice methods covered by or included in the Hematocrit Technology for the life of any protectable rights in the Hematocrit Technology.

License Property
Hematocrit is the percentage of blood volume made up by red blood cells and is a common laboratory test performed invasively by drawing a blood sample from the patient.

Licensor's application for a patent entitled 'Method and Apparatus for Non-Invasively Determining Hematocrit' was allowed by the U.S. Patent and Trademark Office, and such patent issued on June 18, 1996, as Patent No. 5,526,808 with a term of 17 years and an expiration date of June 18, 2013. Licensor has been issued three additional patents, Patent No. 5,642,734, Patent No. 6,128,518 and Patent No. 6,766,191, each of which claims priority from October 4, 1990, the date of the first patent's filing, and each of which has an

expiration date of October 4, 2010.

IPSCIO Record ID: 2281

License Grant
The Licensor agreed to grant the Company a world-wide, non-exclusive license under the patent (U.S. Patent No. 4,686,479) which was the subject of the lawsuit, to manufacture and sell analyzers and cartridges that determine hematocrit levels. Hematocrit is the percentage by volume of packed red blood cells in a given sample of blood after centrifugation.
License Property
Licensed Products shall mean (i) any analyzer made, used, sold, offered for sale, or imported by i-STAT with an algorithm or software to determine hematocrit using the Licensed Methods, including, but not limited to, the i-STAT(R) System, the i-STAT(R) Portable Clinical Analyzer, or the i-STAT 1.

Licensed Methods shall mean (i) any method that i-STAT has used for determining hematocrit in its commercially-available analyzers from the issuance of the Patent through and including December 31, 2000, including, but not limited to, any method for determining hematocrit used in the i-STAT(R) System, the i-STAT(R) Portable Clinical Analyzer, or the i-STAT 1; and (ii) any method for determining hematocrit claimed in the Patent.

Field of Use
The rights apply to determining hematocrit.

IPSCIO Record ID: 3240

License Grant
The cross-licensing agreement with the Licensee, who is Licensor's development partner, is granting an exclusive, perpetual and worldwide license, with sublicense rights, to use all Masimo SET® owned by the Licensor for the monitoring of non-vital signs measurements and to develop and sell devices incorporating Masimo SET® for monitoring non-vital signs measurements in the Licensee Market.

The Licensor also granted the Licensee a non-exclusive, perpetual and worldwide license, with sublicense rights, to use Masimo SET® for the measurement of vital signs in the Licensee  Market.

Pursuant to the Cross-Licensing Agreement, the Licensor has licensed from the Licensee the right to make and distribute products in the Licensor Market that utilize rainbow® technology for the measurement of only carbon monoxide, methemoglobin, fractional arterial oxygen saturation and hemoglobin, which includes hematocrit

License Property
The Licensor invented Masimo Signal Extraction Technology®, or Masimo SET®, which provides the capabilities of Measure-Through Motion and Low Perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. Pulse oximetry is the noninvasive measurement of the oxygen saturation level of arterial blood, or the blood that delivers oxygen to the body's tissues, and pulse rate.

Rainbow® SET platform utilizing both Masimo SET® and licensed rainbow® technology, includes devices cleared by the U.S. Food and Drug Administration, to noninvasively and continuously monitor multiple measurements that previously required invasive or complicated procedures.

Field of Use
The Licensee Market is defined as any product market in which a product is intended to be used by a patient or pharmacist rather than a professional medical caregiver regardless of the particular location of the sale, including sales to doctors, hospitals, alternate care market professionals or otherwise, provided the product is intended to be recommended, or resold, for use by the patient or pharmacist.

IPSCIO Record ID: 28337

License Grant
Licensor hereby grants to Chinese Licensee, pursuant to the terms of this Distribution Agreement, an exclusive license to sell and distribute the Products only within the following geographical areas  Australia, New Zealand and the countries of Asia (including without limitation, Indonesia, Malaysia and the island countries of the Western Pacific Rim; but excluding Russia, Turkey and the countries of the Middle East from Iran and to the  west). Licensor shall not grant any license to any third party to sell or distribute the Products in the License Areas nor shall Licensee sell or distribute the Products outside of the License Areas.
License Property
The Licensor is a medical products research and development company.  It has developed a method for measuring hematocrit non-invasively (without drawing blood) and has applied for and/or received three (3) patents from the U.S.  Patent and Trademark Office. As of February 15, 1995, the application for a patent entitled 'Method and Apparatus for Non-invasively   Determining Hematocrit was allowed by the U.S.  Patent and Trademark Office, and such patent issued on June 18, 1996, as Patent No. 5526808 with term of 17 years.  Licensor filed an application for an additional patent, which claims priority from October 4, 1990, the date of the first patent's filing. The second patent was issued on July 1 1997 as patent No. 5,642,734, Method and Apparatus for Noninvasively Determining Hematocrit As of December 21, 1999, Licensor received a first office action notice of allowance on a third patent, 'System and Method for Invivo Hematocrit Measurement Using Impedance and Pressure Plethysmography.' On October 3, 2000 this patent was issued as patent No. 6,128,518.  On May 16, 2000 licensor  filled for a fourth patent System and Method for In-Vivo Hematocrit Measurement Using Impedance and Pressure Plethysmography. This patent application is currently pending. The methods and procedures to measure hematocrit non-invasively,  including without limitation, the patents and technologies incorporated in the three patents and patent applications described above, are collectively referred to herein as the  'Licensor's Hematocrit Technology'.
Field of Use
This agreement pertains to the medical products industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.